The study of the biological characteristics of lung cancer is gaining more and more interest both because of their potential role as prognostic indicators and for therapeutic reasons. The DNA content estimated by flow cytometry in surgical samples of non-small cell lung cancer (NSCLC) has already been demonstrated to be correlated with survival in these patients. From July 1990 to February 1992 we analyzed the DNA distribution of bronchoscopic biopsies from 88 patients with lung cancer (18 small cell lung cancer, SCLC, and 68 NSCLC, two unspecified histology). Twenty-eight tumors (34.6%) had a diploid DNA distribution, while 53 were aneuploid (65.4%). A correlation was found between DNA ploidy and survival. Evaluation of the DNA content in bronchoscopic samples in a large series of patients could determine the role of this analysis prior to surgery in NSCLC and its value as a marker with respect to prognosis and response to therapy in SCLC.
SandbergA.A.. The chromosomes in human cancer and leukemia.New York: Elsevier/North Holland, 1980.
2.
TribukaitB.. Clinical DNA flow cytometry.Med Oncol Tumor Pharmacother1984; 1: 211–8.
3.
AtkinN.B., KavR.. Prognostic significance of modal DNA value and other factors in malignant tumours, based on 1465 cases.Br J Cancer1979; 40: 210–21.
4.
DiamondL.W., NathwaniB.N., RappaportH.. Flow cytometry in the diagnosis and classification of malignant lymphoma and leukemia.Cancer1982; 50: 1122–7.
5.
MerkelD.E., DresslerL.G., McGuireW.L.. Flow cytometry, cellular DNA content and prognosis in human malignancy.J Clin Oncol1987; 10: 1690–703.
6.
ZimmermannP.V., BintM.H., HawsonG.A.T.. Ploidy as a prognostic determination in surgically treated lung cancer.Lancet1987; 2: 530–3.
7.
MoranR.E., MelamedM.R.. Flow cytometric analysis of human lung cancer.Anal Quant Cytol1984; 6: 99–104.
8.
Tirindelli-DanesiD., TeodoriL., MauroF.. Prognostic significance of flow cytometry in lung cancer: a 5-year study.Cancer1987; 60: 844–51.
9.
DazziH., TharcherN., HasletonP.S.. DNA analysis by flow cytometry in non small cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival.Respir Med1990; 84: 217–23.
10.
MiyamotoH., HaradaM., IsobeH.. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.Cancer Res1991; 51: 6346–50.
11.
SahinA.A., RoJ.Y., El-NaggarA.K.. Flow cytometric analysis of the DNA content of non small cell lung cancer.Cancer1990; 65: 530–7.
12.
IsobeH., MyiamotoH., ShimizuT.. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer.Cancer1990; 65: 1391–5.
13.
AsamuraH., NakajimaT., MukaiK.. Nuclear DNA content by cytofluorometry of stage 1 adenocarcinoma of the lung in relation to postoperative recurrence.Chest1989; 96: 312–8.
14.
CarpN.Z., EllisonD.D., BrophyP.F.. DNA content in correlation with postsurgical stage in non-small cell lung cancer.Ann Thorac Surg1992; 53: 680–3.
15.
TanakaI., MasudaR., FuruhataY., InoueM., FujiwaraM., TakemuraT.. Flow cytometric analysis of the DNA content of adenocarcinoma of the lung, especially for patients with stage 1 disease with long term follow-up.Cancer1995; 75: 2461–5.
16.
CostaA., SilvestriniR., MochenC.. P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer.Br J Cancer1996; 73: 914–9.
17.
VolmM., DringsP., MatternJ.. Prognostic significance and resistance-predictive tests in non-small cell lung carcinoma.Cancer1985; 56: 1396–403.
18.
TeodoriL., Tirindelli-DanesiD., MauroF.. Non small cell carcinoma: Tumor characterization on the basis of flow cytometrically determined cellular heterogeneity.Cytometry1983; 4: 174–83.
19.
CibasE.S., MelamedM.R., ZamanM.B.. The effect of tumour size and tumour cell DNA content on the survival of patients with stage I adenocarcinoma of the lung.Cancer1989; 63: 1552–6.
20.
SchmidtR.A., RuschW., PiantadosiS.. A flow cytometric study of non-small cell lung cancer classified as T1N0.Cancer1992; 69: 78–85.
21.
BunnP.A., CarneyD.N., GazdarA.F.. Diagnostic and biological implications of flow cytometric DNA content analysis in lung cancer.Cancer Res1983; 43: 5026–32.
22.
Ten VeldeG.P.M., SchutteB., VermeulenA.. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small cell lung cancer.Eur J Cancer Clin Oncol1988; 24: 455–60.
23.
AbeS., OguraS., NakajimaI.. Small-cell-type poorly differentiated squamous cell carcinoma of the lung. Cytologic, immunohistochemical and nuclear DNA content analysis.Anal Quant Cytol Histol1990; 12: 73–7.
24.
BlondalT., PontenJ.. DNA ploidy in small cell carcinoma of the lung.Anticancer Res1983; 3: 47–52.
25.
HanedaH., MiyamotoH., IsobeH.. Accuracy of the bronchoscopic DNA content analysis of non-small-cell lung cancer.J Surg Oncol1992; 49: 182–8.
26.
AbeS., TsunetaY., MakimuraS.. Nuclear DNA content as an indicator of chemosensitivity in small cell carcinoma of the lung.Anal Quant Cytol Histol1987; 9: 425–8.
27.
MarubiniE., ValsecchiM.G.. Analysing survival data from clinical trials and observational studies.Chichester, England: Wiley & Sons, 1995.
28.
Stata Corporation.Intercooled Stata 8.0 for Windows.College Station, TX, USA: Stata Corporation, 2003.
29.
HofmannH.S., KnolleJ., BahnH.. Flow cytometric analysis of DANN content and proliferation and immunohistochemistry staining of Ki-67 in non-small cell lung cancer.J Cardiovasc Surg2001; 42: 455–60.
30.
CareyF.A., FabbroniG., LambD.. Expression of proliferating cell nuclear antigen in lung cancer: a systematic study and correlation with DNA ploidy.Histopathology1992; 20: 499–503.
31.
ASCO Special Article.Clinical practice guidelines for the treatment of unresectable non small cell lung cancer.J Clin Oncol1997; 15: 2296–3018.
32.
VokesE.E., ChoyH., GandaraD., MattsonK.. Adjuvant and neoadjuvant treatments for NSCLC.Lung Cancer2002; 38(Suppl 4): 29–35.
33.
SchwartzJ.L., MurnaneJ., WeichselbaumR.R.. The contribution of DANN ploidy to radiation sensitivity in human tumour cell lines.Br J Cancer1999; 79: 744–7.
34.
SenS., ReddyV.G., KhannaN.. A comparative study of telomerase activity in sputum, bronchial washing and biopsy specimens of lung cancer.Lung Cancer2001; 33: 41–9.
35.
KristiansenG., YuY., PetersenS.. Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer.Eur J Cancer2001; 37: 1089–95.
36.
GarinisG.A., GorgouilisV.G., MariatosG.. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).J Pathol2001; 193: 55–65.
